NCT02104063 (MRI-PET) is a clinical trial of MRI-PET in Squamous Cell Carcinoma of the Penis, sponsored by Queen Mary University of London.

Who is sponsoring NCT02104063?

NCT02104063 is sponsored by Queen Mary University of London.

What drugs are being tested in NCT02104063?

Interventions in NCT02104063: MRI-PET.

What condition does NCT02104063 study?

NCT02104063 studies Squamous Cell Carcinoma of the Penis.

Is NCT02104063 still recruiting?

NCT02104063 is currently completed. Last updated 10 March 2025.

Last reviewed 2025-03-10 · How we verify

NCT02104063: MRI-PET

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET]

Completed Last updated 10 March 2025

What this trial tests

trial testing MRI-PET in Squamous Cell Carcinoma of the Penis in 78 participants. Completed in 22 July 2016.

Timeline

22 July 2013

Primary endpoint
22 July 2016

22 July 2016

Quick facts

Lead sponsor	Queen Mary University of London
Status	Completed
Study type	OBSERVATIONAL
Enrollment	78
Start date	22 July 2013
Primary completion	22 July 2016
Estimated completion	22 July 2016
Sites	1 location across United Kingdom

Drugs / interventions tested

MRI-PET

Conditions studied

Squamous Cell Carcinoma of the Penis — all drugs for Squamous Cell Carcinoma of the Penis →

Sponsor

Queen Mary University of London

Who can join

18 and older, male only, with Squamous Cell Carcinoma of the Penis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The presence of metastatic disease in the lymph nodes within the groin is the most important factor in predicting the long-term outcome for patients diagnosed with penile cancer. In the majority of patients diagnosed with penile cancer obvious abnormalities cannot be felt in the groin even though the cancer may have already spread to the lymph nodes in the groin. In these patients, a procedure called Dynamic Sentinel Lymph Node Biopsy (DSLB) is required to determine if the cancer has spread to the lymph nodes in the groin. In DSLB a radioactive substance is injected at the site of the penile cancer and then travels to the lymph nodes in the groin which are then biopsied. This procedure requires a general anaesthetic and an in-patient hospital stay. In approximately 20% of patients with penile cancer obvious abnormalities can be felt in the lymph nodes in the groin. However, any abnormality detected may not necessarily be due to metastatic disease. In order to confirm if metastatic disease is present in the lymph nodes of these patients a biopsy is also required. However in these patients the lymph nodes are detected and biopsied using an ultrasound scan rather than by passing a radioactive substance into the body. MRI-PET is a new procedure which combines conventional MRI (Magnetic Resonance Imaging) and PET (Positron Emission Tomography) scans into one scan. MRI - PET scans create very clear pictures of internal body structures. MRI-PET is a non-invasive procedure which can be performed on an out-patient basis. The accuracy of MRI-PET in detecting metastatic penile cancer is not known. The main purpose of this study is to establish the effectiveness of MRI-PET compared to DSLB and ultrasound guided biopsy in detecting the presence of metastatic disease in the lymph nodes of patients with penile cancer. If effective, MRI-PET could replace the invasive procedures currently required for detection of metastatic penile cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Squamous Cell Carcinoma of the Penis

Currently open trials in the same condition.

NCT06161532 — Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade · Phase 2 · recruiting

Other Queen Mary University of London trials

Trials by the same sponsor.

NCT07246005 — LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus · Phase 2 · not yet recruiting
NCT07165678 — CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2) · NA · not yet recruiting
NCT06937372 — Delivery and Implementation of a Randomised Crossover Trial on Thrombosis · NA · not yet recruiting
NCT06600438 — Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial · NA · not yet recruiting
NCT06987045 — Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02104063 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Queen Mary University of London
Last refreshed: 10 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02104063.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing